vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and GCM Grosvenor Inc. (GCMG). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $177.1M, roughly 1.0× GCM Grosvenor Inc.). GCM Grosvenor Inc. runs the higher net margin — 32.8% vs 13.3%, a 19.5% gap on every dollar of revenue. On growth, GCM Grosvenor Inc. posted the faster year-over-year revenue change (7.2% vs -1.8%). GCM Grosvenor Inc. produced more free cash flow last quarter ($175.0M vs $24.6M). Over the past eight quarters, GCM Grosvenor Inc.'s revenue compounded faster (27.5% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
GCM Grosvenor is an American alternative asset management firm, with approximately $76 billion in assets under management and approximately 530 professionals as of 2023.
AMPH vs GCMG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $177.1M |
| Net Profit | $24.4M | $58.2M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 30.9% |
| Net Margin | 13.3% | 32.8% |
| Revenue YoY | -1.8% | 7.2% |
| Net Profit YoY | -35.7% | 149.2% |
| EPS (diluted) | $0.51 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $177.1M | ||
| Q3 25 | $191.8M | $135.0M | ||
| Q2 25 | $174.4M | $119.7M | ||
| Q1 25 | $170.5M | $125.8M | ||
| Q4 24 | $186.5M | $165.3M | ||
| Q3 24 | $191.2M | $122.9M | ||
| Q2 24 | $182.4M | $117.0M | ||
| Q1 24 | $171.8M | $108.9M |
| Q4 25 | $24.4M | $58.2M | ||
| Q3 25 | $17.4M | $10.5M | ||
| Q2 25 | $31.0M | $15.4M | ||
| Q1 25 | $25.3M | $463.0K | ||
| Q4 24 | $38.0M | $7.6M | ||
| Q3 24 | $40.4M | $4.2M | ||
| Q2 24 | $37.9M | $4.8M | ||
| Q1 24 | $43.2M | $2.1M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 30.9% | ||
| Q3 25 | 13.2% | 32.7% | ||
| Q2 25 | 24.2% | 16.1% | ||
| Q1 25 | 21.9% | 12.2% | ||
| Q4 24 | 24.2% | 26.4% | ||
| Q3 24 | 29.8% | 20.3% | ||
| Q2 24 | 30.3% | 17.8% | ||
| Q1 24 | 27.9% | -14.7% |
| Q4 25 | 13.3% | 32.8% | ||
| Q3 25 | 9.0% | 7.8% | ||
| Q2 25 | 17.8% | 12.9% | ||
| Q1 25 | 14.8% | 0.4% | ||
| Q4 24 | 20.4% | 4.6% | ||
| Q3 24 | 21.1% | 3.4% | ||
| Q2 24 | 20.8% | 4.1% | ||
| Q1 24 | 25.1% | 2.0% |
| Q4 25 | $0.51 | $0.23 | ||
| Q3 25 | $0.37 | $0.16 | ||
| Q2 25 | $0.64 | $0.05 | ||
| Q1 25 | $0.51 | $-0.02 | ||
| Q4 24 | $0.74 | $0.09 | ||
| Q3 24 | $0.78 | $0.03 | ||
| Q2 24 | $0.73 | $0.04 | ||
| Q1 24 | $0.81 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $242.1M |
| Total DebtLower is stronger | $608.7M | $428.4M |
| Stockholders' EquityBook value | $788.8M | $27.0M |
| Total Assets | $1.6B | $813.8M |
| Debt / EquityLower = less leverage | 0.77× | 15.87× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $242.1M | ||
| Q3 25 | $276.2M | $182.7M | ||
| Q2 25 | $231.8M | $136.3M | ||
| Q1 25 | $236.9M | $94.5M | ||
| Q4 24 | $221.6M | $89.5M | ||
| Q3 24 | $250.5M | $98.4M | ||
| Q2 24 | $217.8M | $73.9M | ||
| Q1 24 | $289.6M | $41.9M |
| Q4 25 | $608.7M | $428.4M | ||
| Q3 25 | $608.6M | $429.3M | ||
| Q2 25 | $607.7M | $430.2M | ||
| Q1 25 | $603.9M | $431.1M | ||
| Q4 24 | $601.6M | $432.0M | ||
| Q3 24 | $596.4M | $432.9M | ||
| Q2 24 | $586.9M | $433.8M | ||
| Q1 24 | $594.0M | $384.0M |
| Q4 25 | $788.8M | $27.0M | ||
| Q3 25 | $776.7M | $-7.4M | ||
| Q2 25 | $757.5M | $-12.3M | ||
| Q1 25 | $751.3M | $-28.3M | ||
| Q4 24 | $732.3M | $-27.6M | ||
| Q3 24 | $727.7M | $-31.9M | ||
| Q2 24 | $713.3M | $-28.5M | ||
| Q1 24 | $672.4M | $-26.4M |
| Q4 25 | $1.6B | $813.8M | ||
| Q3 25 | $1.7B | $685.9M | ||
| Q2 25 | $1.6B | $636.9M | ||
| Q1 25 | $1.6B | $579.8M | ||
| Q4 24 | $1.6B | $612.7M | ||
| Q3 24 | $1.5B | $575.0M | ||
| Q2 24 | $1.5B | $543.9M | ||
| Q1 24 | $1.6B | $497.3M |
| Q4 25 | 0.77× | 15.87× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $183.5M |
| Free Cash FlowOCF − Capex | $24.6M | $175.0M |
| FCF MarginFCF / Revenue | 13.4% | 98.8% |
| Capex IntensityCapex / Revenue | 4.5% | 4.8% |
| Cash ConversionOCF / Net Profit | 1.35× | 3.16× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $326.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $183.5M | ||
| Q3 25 | $52.6M | $79.8M | ||
| Q2 25 | $35.6M | $42.0M | ||
| Q1 25 | $35.1M | $33.3M | ||
| Q4 24 | $29.0M | $148.8M | ||
| Q3 24 | $60.0M | $69.0M | ||
| Q2 24 | $69.1M | $17.5M | ||
| Q1 24 | $55.3M | $24.2M |
| Q4 25 | $24.6M | $175.0M | ||
| Q3 25 | $47.2M | $78.3M | ||
| Q2 25 | $25.0M | $40.8M | ||
| Q1 25 | $24.4M | $32.1M | ||
| Q4 24 | $16.6M | $132.0M | ||
| Q3 24 | $46.2M | $62.2M | ||
| Q2 24 | $63.1M | $12.8M | ||
| Q1 24 | $46.5M | $20.0M |
| Q4 25 | 13.4% | 98.8% | ||
| Q3 25 | 24.6% | 58.0% | ||
| Q2 25 | 14.3% | 34.1% | ||
| Q1 25 | 14.3% | 25.5% | ||
| Q4 24 | 8.9% | 79.9% | ||
| Q3 24 | 24.1% | 50.6% | ||
| Q2 24 | 34.6% | 10.9% | ||
| Q1 24 | 27.1% | 18.4% |
| Q4 25 | 4.5% | 4.8% | ||
| Q3 25 | 2.8% | 1.1% | ||
| Q2 25 | 6.1% | 1.0% | ||
| Q1 25 | 6.3% | 0.9% | ||
| Q4 24 | 6.7% | 10.1% | ||
| Q3 24 | 7.2% | 5.5% | ||
| Q2 24 | 3.3% | 4.0% | ||
| Q1 24 | 5.1% | 3.9% |
| Q4 25 | 1.35× | 3.16× | ||
| Q3 25 | 3.03× | 7.61× | ||
| Q2 25 | 1.15× | 2.72× | ||
| Q1 25 | 1.39× | 71.84× | ||
| Q4 24 | 0.76× | 19.54× | ||
| Q3 24 | 1.48× | 16.60× | ||
| Q2 24 | 1.82× | 3.64× | ||
| Q1 24 | 1.28× | 11.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
GCMG
| Asset Management1 | $108.6M | 61% |
| Management Service Incentive Performance Fees | $61.7M | 35% |
| Management Service Incentive Carried Interest | $5.1M | 3% |
| Service Other | $1.8M | 1% |
